Abstract Number: 2224 • 2012 ACR/ARHP Annual Meeting
Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age At Diagnosis
Background/Purpose: While AS is traditionally recognized as a predominantly male disease, the impact of gender differences on AS pathogenesis has not been clearly established. Specifically,…Abstract Number: 1381 • 2012 ACR/ARHP Annual Meeting
Non-Radiographic Spondyloarthritis Has Greater Work Instability Than Other Spondyloarthritis Subtypes in a National Database
Background/Purpose: Clinical subsets of spondyloarthritis (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA) can be associated with significant impact on work performance and…Abstract Number: 591 • 2012 ACR/ARHP Annual Meeting
Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived
Background/Purpose: Current inflammatory biomarkers, such as CRP, have insufficient sensitivity and specificity to be broadly accepted for diagnosis and prognosis of AS. We hypothesized, that…Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…Abstract Number: 2225 • 2012 ACR/ARHP Annual Meeting
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Background/Purpose: Secukinumab has shown to be well tolerated and effective in active ankylosing spondylitis (AS) patients in a proof-of-concept trial1. Briefly, at Week (Wk) 6,…Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…Abstract Number: 592 • 2012 ACR/ARHP Annual Meeting
Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis
Background/Purpose: Cartilage degradation and inflammation of synovial and connective tissue are key events in inflammatory arthropathies such as SpA. Presently there are no prognostic tools…Abstract Number: 2652 • 2012 ACR/ARHP Annual Meeting
Benefits of Aerobic Training in Patients with Ankylosing Spondylitis Are Not Coupled by Effects On Cytokines: A Randomized Controlled Trial
Background/Purpose: Ankylosing Spondylitis (AS) is a systemic inflammatory disease that causes deterioration of physical capacity. Although exercises remain essential in the treatment, the literature lacks…Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…Abstract Number: 1384 • 2012 ACR/ARHP Annual Meeting
The Frequency of Non-Radiographic Axial Spondyloarthritis in Relation to Symptom Duration in Patients Referred Because of Chronic Back Pain: Results From the Berlin Early Spondyloarthritis Clinic
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial SpA (=ankylosing spondylitis – AS) are considered currently as two stages of axial SpA. We reported recently…Abstract Number: 597 • 2012 ACR/ARHP Annual Meeting
Investigating the Genetic Association Between ERAP1 and Spondyloarthritis
Background/Purpose: A robust association was recently identified between polymorphisms in the non-major histocompatibility complex gene ERAP1 and ankylosing spondylitis (AS) in several populations. The aim…Abstract Number: 2235 • 2012 ACR/ARHP Annual Meeting
How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis…Abstract Number: 1385 • 2012 ACR/ARHP Annual Meeting
Increased Body Mass Index in Ankylosing Spondylitis Is Associated with a Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise
Background/Purpose: In Ankylosing Spondylitis (AS) the effect of obesity on disease characteristics and exercise perceptions is unknown. Exercise is an essential component in the management…Abstract Number: 598 • 2012 ACR/ARHP Annual Meeting
The Non-Synonymous Polymorphism IL23R Arg381Gln Is Associated with Ankylosis in Spondyloarthritis
Background/Purpose: Spondyloarthritis (SpA) is a group of articular disorders sharing genetic background. Single-nucleotide polymorphisms (SNP) of the interleukin 23 receptor (IL23R) gene have been reproducibly…Abstract Number: 2213 • 2012 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Is Strongly Related to Clinical Spine Fractures Independently of Drugs Use: A Register-Based Case-Control Study
TITLE: "Ankylosing Spondylitis is strongly related to clinical spine fractures independently of drugs use: a register-based case-control study."Background/Purpose: Ankylosing Spondylitis (AS) is associated not only…